Safety and Effectiveness of an Immunobiological Drug in CoViD-19
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The aims of this study is to analyze the efficacy and safety of a passive immunotherapy
strategy using hyperimmune equine serum known as Anti-SARS-CoV-2 elaborated by the National
Institute for the Production of Biologicals (ANLIS-Malbrán) as an addition to the standard
therapeutic approach for hospitalized patients with COVID-19, in patients with severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection aged 18 to 80 years.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Administracion Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbran